345 related articles for article (PubMed ID: 16172190)
1. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers.
Rau KM; Kang HY; Cha TL; Miller SA; Hung MC
Endocr Relat Cancer; 2005 Sep; 12(3):511-32. PubMed ID: 16172190
[TBL] [Abstract][Full Text] [Related]
2. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer.
Platz EA; Giovannucci E
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):237-53. PubMed ID: 15663987
[TBL] [Abstract][Full Text] [Related]
3. [Hormone therapy--recent advances].
Matsumoto K; Noguchi S
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2816-23. PubMed ID: 2959202
[TBL] [Abstract][Full Text] [Related]
4. Is dehydroepiandrosterone a hormone?
Labrie F; Luu-The V; Bélanger A; Lin SX; Simard J; Pelletier G; Labrie C
J Endocrinol; 2005 Nov; 187(2):169-96. PubMed ID: 16293766
[TBL] [Abstract][Full Text] [Related]
5. Endocrine therapy in cancer.
Stoll BA
Practitioner; 1979 Feb; 222(1328):211-7. PubMed ID: 86186
[TBL] [Abstract][Full Text] [Related]
6. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
[TBL] [Abstract][Full Text] [Related]
7. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention.
Jordan VC
Cancer Res; 2009 Feb; 69(4):1243-54. PubMed ID: 19208829
[TBL] [Abstract][Full Text] [Related]
8. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women.
Eliassen AH; Missmer SA; Tworoger SS; Spiegelman D; Barbieri RL; Dowsett M; Hankinson SE
J Natl Cancer Inst; 2006 Oct; 98(19):1406-15. PubMed ID: 17018787
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms leading to the development of hormone-resistant prostate cancer.
Kasper S; Cookson MS
Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
[TBL] [Abstract][Full Text] [Related]
10. Hormone treatment for prostate cancer: current issues and future directions.
Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
[TBL] [Abstract][Full Text] [Related]
11. Hormone therapy for cancer. II. Breast and prostate.
Drug Ther Bull; 1970 Jul; 8(16):61-3. PubMed ID: 5453278
[No Abstract] [Full Text] [Related]
12. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer.
Gligorov J; Lotz JP
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():53-66. PubMed ID: 19101794
[TBL] [Abstract][Full Text] [Related]
13. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Lane HA; Lebwohl D
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
[TBL] [Abstract][Full Text] [Related]
14. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S; Schiff R
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factor-1 in human breast and prostate cancer.
Kimbro KS; Simons JW
Endocr Relat Cancer; 2006 Sep; 13(3):739-49. PubMed ID: 16954428
[TBL] [Abstract][Full Text] [Related]
16. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
17. The potential of hormone receptors in the treatment of various cancers.
Neifeld JP
Oncology (Williston Park); 1989 Aug; 3(8):57-62. PubMed ID: 2562401
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of prostate cancer progression to androgen independence.
McPhaul MJ
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):373-88. PubMed ID: 18471793
[TBL] [Abstract][Full Text] [Related]
19. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario.
Carruba G
J Cell Biochem; 2007 Nov; 102(4):899-911. PubMed ID: 17786930
[TBL] [Abstract][Full Text] [Related]
20. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
Gururaj AE; Rayala SK; Vadlamudi RK; Kumar R
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1001s-1007s. PubMed ID: 16467116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
